As­traZeneca's res­pi­ra­to­ry group spells out some set­backs in its lat­est PhI­II read­out for GSK COPD ri­val PT010

As­traZeneca $AZN field­ed the Phase III da­ta on its new triple-drug com­bi­na­tion COPD ther­a­py that it in­tends to use to chal­lenge Glax­o­SmithK­line. And the phar­ma gi­ant has some prob­lems to work out.

As re­port­ed near the be­gin­ning of the year, As­traZeneca’s KRO­NOS study of­fered pos­i­tive re­sults for PT010 (budes­onide/ gly­copy­rro­ni­um/for­moterol fu­marate) com­pared to Bevespi Aeros­phere and Sym­bi­cort, two 2-drug ther­a­pies in the field across a range of end­points. But on clos­er look their con­tender to take on GSK’s Trel­e­gy failed to sig­nif­i­cant­ly dis­tin­guish it­self in the rate of mod­er­ate or se­vere COPD ex­ac­er­ba­tions ver­sus PT009 and Sym­bi­cort and al­so failed the 24-week com­par­i­son on FEV1 re­sponse with Bevespi.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER